Which vitamin D in CKD-MBD? the time of burning questions

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Galassi, Andrea ^a   Bellasi, Antonio ^b,c   Auricchio, Sara ^a   Papagni, Sergio ^d   Cozzolino, Mario ^c  

^a DESIO HOSPITAL   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Dialysis Center CBH Città di Bisceglie   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; 7 DEHYDROCHOLESTEROL; ALBUMIN; ALFACALCIDOL; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM PHOSPHATE; CINACALCET; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; ERGOSTEROL; FALECALCITRIOL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR ACTIVATOR;

BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; COCHRANE LIBRARY; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY FAILURE; META ANALYSIS; MICROALBUMINURIA; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT SATISFACTION; PHOSPHATE BLOOD LEVEL; PLEIOTROPY; PRESCRIPTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; ANIMAL; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; RENAL OSTEODYSTROPHY; TREATMENT OUTCOME;

ANIMALS; EVIDENCE-BASED MEDICINE; HUMANS; RENAL OSTEODYSTROPHY; TREATMENT OUTCOME; VITAMIN D;

EID: 84883152214     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/864012     Document Type: Review

References (100)

1. Bhuriya R., Li S., Chen S.-C., McCullough P. A., Bakris G. L., Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD Stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases 2009 53 supplement 4 S3 S10 2-s2.0-61749084092 10.1053/j.ajkd.2008.11.029
2. Kovesdy C. P., Ahmadzadeh S., Anderson J. E., Kalantar-Zadeh K., Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney International 2008 73 11 1296 1302 2-s2.0-43749124436 10.1038/ki.2008.64
3. Schumock G. T., Andress D. L., Marx S. E., Sterz R., Joyce A. T., Kalantar-Zadeh K., Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron 2009 113 1 c54 c61 2-s2.0-67649873051 10.1159/000228076
4. Block G. A., Klassen P. S., Lazarus M., Ofsthun N., Lowrie E. G., Chertow G. M., Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology 2004 15 8 2208 2218
5. Kalantar-Zadeh K., Kuwae N., Regidor D. L., Kovesdy C. P., Kilpatrick R. D., Shinaberger C. S., McAllister C. J., Budoff M. J., Salusky I. B., Kopple J. D., Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney International 2006 70 4 771 780 2-s2.0-33745210682 10.1038/sj.ki.5001514
6. KDIGO, Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney International 2009 76 supplement 113 S70 S89
7. Cozzolino M., Bruschetta E., Stucchi A., Ronco C., Cusi D., Role of vitamin D receptor activators in cardio-renal syndromes. Seminars in Nephrology 2012 32 1 63 69 2-s2.0-84857375103 10.1016/j.semnephrol.2011.11.009
8. Cozzolino M., Ronco C., The impact of paricalcitol on left ventricular hypertrophy. Contributions to Nephrology 2011 171 161 165 2-s2.0-79958168695 10.1159/000327170
9. Holick M., Vitamin D deficiency. The New England Journal of Medicine 2007 357 3 266 281
10. Nair R., Maseeh A., Vitamin D the "sunshine" vitamin. Journal of Pharmacology and Pharmacotherapeutics 2012 3 2 118 126
11. MacDonald H. M., Mavroeidi A., Fraser W. D., Darling A. L., Black A. J., Aucott L., O'Neill F., Hart K., Berry J. L., Lanham-New S. A., Reid D. M., Sunlight and dietary contributions to the seasonal vitamin D status of cohorts of healthy postmenopausal women living at northerly latitudes a major cause of concern. Osteoporosis International 2010 92 6 1393 1398
12. Rizzoli R., Boonen S., Brandi M. L., Bruyère O., Cooper C., Kanis J. A., Kaufman J. M., Ringe J. D., Weryha G., Reginster J. Y., Vitamin D supplementation in elderly or postmenopausal women a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Current Medical Research and Opinion 2013 29 4 305 301
13. Forman J. P., Giovannucci E., Holmes M. D., Bischoff-Ferrari H. A., Tworoger S. S., Willett W. C., Curhan G. C., Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007 49 5 1063 1069 2-s2.0-34247893803 10.1161/HYPERTENSIONAHA.107.087288
14. Wang L., Song Y., Manson J. E., Pilz S., März W., Michaëlsson K., Lundqvist A., Jassal S. K., Barrett-Connor E., Zhang C., Eaton C. B., May H. T., Anderson J. L., Sesso H. D., Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease a meta-analysis of prospective studies. Circulation 2012 5 6 819 829
15. Forouhi N. G., Luan J., Cooper A., Boucher B. J., Wareham N. J., Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance the medical research council ely prospective study 1990-2000. Diabetes 2008 57 10 2619 2625 2-s2.0-58149346072 10.2337/db08-0593
16. Ginde A. A., Mansbach J. M., Camargo C. A. Jr., Association between Serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Archives of Internal Medicine 2009 169 4 384 390 2-s2.0-61449136072 10.1001/archinternmed.2008.560
17. Pilz S., Kienreich K., Tomaschitz A., Ritz E., Lerchbaum E., Obermayer-Pietsch B., Matzi V., Lindenmann J., Marz W., Gandini S., Dekker J. M., Vitamin d and cancer mortality systematic review of prospective epidemiological studies. Anti-Cancer Agents in Medicinal Chemistry 2013 13 1 107 117
18. Schöttker B., Haug U., Schomburg L., Köhrle J., Perna L., Müller H., Holleczek B., Brenner H., Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer and respiartory disease mortality in a large cohort study. The American Journal of Clinical Nutrition 2013 97 4 782 793
19. Ravani P., Malberti F., Tripepi G., Pecchini P., Cutrupi S., Pizzini P., Mallamaci F., Zoccali C., Vitamin D levels and patient outcome in chronic kidney disease. Kidney International 2009 75 1 88 95 2-s2.0-58149156441 10.1038/ki.2008.501
20. Ureña-Torres P., Metzger M., Haymann J. P., Karras A., Boffa J.-J., Flamant M., Vrtovsnik F., Gauci C., Froissart M., Houillier P., Stengel B., Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. American Journal of Kidney Diseases 2011 58 4 544 553 2-s2.0-80053054321 10.1053/j.ajkd.2011.04.029
21. Pilz S., Iodice S., Zittermann A., Grant W. B., Gandini S., Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. American Journal of Kidney Diseases 2011 58 3 374 382 2-s2.0-80051919112 10.1053/j.ajkd.2011.03.020
22. Dusso A. S., Gonzalez E. A., Martin K. J., Vitamin D in chronic kideny disease. Best Practice & Research Clinical Endocrinology & Metabolism 2011 25 4 647 655
23. Saliba W., Barnett O., Rennert H. S., Lavi I., Rennert G., The relationship between serum 25(OH)D and parathyroid hormone levels. American Journal of Medicine 2011 124 12 1165 1170 2-s2.0-81855195928 10.1016/j.amjmed.2011.07.009
24. Gómez-Alonso C., Naves-Díaz M. L., Fernández- Martín J. L., Díaz-López J. B., Fernández-Coto M. T., Cannata-Andía J. B., Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney International, Supplement 2003 63 85 S44 S48 2-s2.0-0037850084
25. Singer R. F., Vitamin D in dialysis defining deficiency and rationale of supplementation. Seminars in Dialysis 2013 26 1 40 46
26. 3 supplementation in raising serum 25-hydroxyvitamin D status a systematic review and meta-analysis. The American Journal of Clinical Nutrition 2012 95 6 1357 1364 10.3945/ajcn.111.031070
27. 2) as a vitamin supplement. The American Journal of Clinical Nutrition 2006 84 4 694 697
28. Horst R. L., Reinhardt T. A., Ramberg C. F., 24-Hydroxylation of 1,25-dihydroxyergocalciferol. An unambiguous deactivation process. Journal of Biological Chemistry 1986 261 20 9250 9256 2-s2.0-0023000957
29. Nigwekar S. U., Bhan I., Thadhani R., Ergocalciferol and cholecalciferol in CKD. American Journal of Kidney Diseases 2012 60 1 139 156 2-s2.0-84860583000 10.1053/j.ajkd.2011.12.035
30. 3 supplementation. The Journal of Clinical Endocrinology & Metabolism 2013 98 973 979
31. Kandula P., Dobre M., Schold J. D., Schreiber M. J. Jr., Mehrotra R., Navaneethan S. D., Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clinical Journal of the American Society of Nephrology 2011 6 1 50 62 2-s2.0-79251474745 10.2215/CJN.03940510
32. Alvarez J. A., Law J., Coakley K. E., Zughaier S. M., Hao L., Shahid Salles K., Wasse H., Gutiérrez O. M., Ziegler T. R., Tangpricha V., High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease a pilot, randomized, double-blind, placebo-controlled trial. The American Journal of Clinical Nutrition 2012 96 3 672 679
33. Shroff R., Wan M., Gullett A., Ledermann S., Shute R., Knott C., Wells D., Aitkenhead H., Manickavasagar B., van't Hoff W., Rees L., Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clinical Journal of the American Society of Nephrology 2012 7 2 216 223 2-s2.0-84857188798 10.2215/CJN.04760511
34. Jean G., Vanel T., Terrat J.-C., Chazot C., Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation. Hemodialysis International 2010 14 4 486 491 2-s2.0-77958581306 10.1111/j.1542-4758.2010.00472.x
35. Palmer S. C., McGregor D. O., Craig J. C., Elder G., Macaskill P., Strippoli G. F., Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews 2009 4 CD005633 2-s2.0-75349111991
36. Kovesdy C. P., Lu J. L., Malakauskas S. M., Andress D. L., Kalantar-Zadeh K., Ahmadzadeh S., Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. American Journal of Kidney Diseases 2012 59 1 58 66 2-s2.0-83655191998 10.1053/j.ajkd.2011.06.027
37. Moe S. M., Saifullah A., LaClair R. E., Usman S. A., Yu Z., A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2010 5 2 299 306 2-s2.0-77749334653 10.2215/CJN.07131009
38. Finch J. L., Tokumoto M., Nakamura H., Yao W., Shahnazari M., Lane N., Slatopolsky E., Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. American Journal of Physiology. Renal Physiology 2010 298 6 F1315 F1322 2-s2.0-77952718903 10.1152/ajprenal.00552.2009
39. Vondracek S. F., Hoody D. W., Combination vitamin D therapy in stage 5 chronic kidney disease. Annals of Pharmacotherapy 2011 45 7-8 1011 1015 2-s2.0-79960801727 10.1345/aph.1P782
40. Jean G., Terrat J.-C., Vanel T., Hurot J.-M., Lorriaux C., Mayor B., Chazot C., Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrology Dialysis Transplantation 2008 23 11 3670 3676 2-s2.0-54149104095 10.1093/ndt/gfn339
41. Tokmak F., Quack I., Schieren G., Sellin L., Rattensperger D., Holland-Letz T., Weiner S. M., Rump L. C., High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrology Dialysis Transplantation 2008 23 12 4016 4020 2-s2.0-56749151146 10.1093/ndt/gfn367
42. Armas L. A., Andukuri R., Barger-Lux J., Heaney R. P., Lund R., 25-hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clinical Journal of the American Society of Nephrology 2012 71 9 428 434
43. Matias P. J., Jorge C., Ferreira C., Borges M., Aires I., Amaral T., Gil C., Cortez J., Ferreira A., Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clinical Journal of the American Society of Nephrology 2010 5 5 905 911 2-s2.0-77952316154 10.2215/CJN.06510909
44. Wasse H., Huang R., Long Q., Singapuri S., Raggi P., Tangpricha V., Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. American Journal of Clinical Nutrition 2012 95 2 522 528 2-s2.0-84856376868 10.3945/ajcn.111.025502
45. Bucharles S., Barberato S. H., Stinghen A. E. M., Gruber B., Piekala L., Dambiski A. C., Custodio M. R., Pecoits-Filho R., Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. Journal of Renal Nutrition 2012 22 2 284 291 2-s2.0-84856351047 10.1053/j.jrn.2011.07.001
46. Delanaye P., Weekers L., Warling X., Moonen M., Smelten N., Médart L., Krzesinski J. M., Cavalier E., Cholecalciferol in haemodialysis patients a randomized, double-blind, proof-of-concept and safety study. Nephrology Dialysis Transplantation 2013 28 7 1779 1786 10.1093/ndt/gft001
47. Coen G., Mantella D., Manni M., Balducci A., Nofroni I., Sardella D., Ballanti P., Bonucci E., 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney International 2005 68 4 1840 1848 2-s2.0-31644439542 10.1111/j.1523-1755.2005.00603.x
48. Wesseling-Perry K., Pereira R. C., Sahney S., Gales B., Wang H.-J., Elashoff R., Jüppner H., Salusky I. B., Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney International 2011 79 1 112 119 2-s2.0-78650265254 10.1038/ki.2010.352
49. Hansen D., Rasmussen K., Pedersen S. M., Rasmussen L. M., Brandi L., Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrology Dialysis Transplantation 2012 27 6 2263 2269
50. Wetmore J. B., Liu S., Krebill R., Menard R., Quarles L. D., Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clinical Journal of the American Society of Nephrology 2010 5 1 110 116 2-s2.0-75749131627 10.2215/CJN.03630509
51. 2-vitamin D and fibroblast growth fcactor -23 (FGF23) in vitamin D insufficiency. The Journal of Clinical Endocrinology & Metabolism 2013 98 2 550 556
52. Kim M. J., Frankel A. H., Donaldson M., Darch S. J., Pusey C. D., Hill P. D., Mayr M., Tam F. W. K., Oral cholecalciferol decreases albuminuria and urinary TGF- β 1 in patients with type 2 diabetic nephropathy on established renin-angiotensin- aldosterone system inhibition. Kidney International 2011 80 8 851 860 2-s2.0-80053571782 10.1038/ki.2011.224
53. 3 repletion in chronic kidney disease stage 3 effects on blood endotoxin activity, inflammatory cytokines, and intestinal permeability. Renal Failure 2013 35 4 497 503 10.3109/0886022X.2013.775696
54. Stubbs J. R., Idiculla A., Slusser J., Menard R., Quarles L. D., Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. Journal of the American Society of Nephrology 2010 21 2 353 361 2-s2.0-77949378067 10.1681/ASN.2009040451
55. Wolf M., Shah A., Gutierrez O., Ankers E., Monroy M., Tamez H., Steele D., Chang Y., Camargo C. A. Jr., Tonelli M., Thadhani R., Vitamin D levels and early mortality among incident hemodialysis patients. Kidney International 2007 72 8 1004 1013 2-s2.0-34948869354 10.1038/sj.ki.5002451
56. Tentori F., Blayney M. J., Albert J. M., Gillespie B. W., Kerr P. G., Bommer J., Young E. W., Akizawa T., Akiba T., Pisoni R. L., Robinson B. M., Port F. K., Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases 2008 52 3 519 530 2-s2.0-49749113618 10.1053/j.ajkd.2008.03.020
57. Cozzolino M., Bruschetta E., Cusi D., Montanari E., Giovenzana M. E., Galassi A., Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate. Expert Opinion on Pharmacotherapy 2012 13 16 2337 2353
58. Fernández-Martín J. L., Carrero J. J., Benedik M., Bos W. J., Covic A., Ferreira A., Floege J., Goldsmith D., Gorriz J. L., Ketteler M., Kramar R., Locatelli F., London G., Martin P. Y., Memmos D., Nagy J., Naves-Díaz M., Pavlovic D., Rodríguez-García M., Rutkowski B., Teplan V., Tielemans C., Verbeelen D., Wüthrich R. P., Martínez-Camblor P., Cabezas-Rodriguez I., Sánchez-Alvarez J. E., Cannata-Andia J. B., COSMOS the dialysis scenario of CKD-MBD in Europe. Nephrology Dialysis Transplantation 2012 28 7 1922 1935 10.1093/ndt/gfs418
59. Llach F., Yudd M., Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. American Journal of Kidney Diseases 2001 38 5 S45 S50 2-s2.0-0034747963
60. Mittman N., Desiraju B., Meyer K. B., Chattopadhyay J., Avram M. M., Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney International 2010 78 supplement 117 S33 S36 2-s2.0-77955141586 10.1038/ki.2010.191
61. Sprague S. M., Llach F., Amdahl M., Taccetta C., Batlle D., Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney International 2003 63 4 1483 1490 2-s2.0-0037378444 10.1046/j.1523-1755.2003. 00878.x
62. Coyne D., Acharya M., Qiu P., Abboud H., Batlle D., Rosansky S., Fadem S., Levine B., Williams L., Andress D. L., Sprague S. M., Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. American Journal of Kidney Diseases 2006 47 2 263 276 2-s2.0-31044455712 10.1053/j.ajkd.2005.10.007
63. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Journal of the American Society of Nephrology 1998 9 8 1427 1432 2-s2.0-0345403572
64. Coburn J. W., Maung H. M., Elangovan L., Germain M. J., Lindberg J. S., Sprague S. M., Williams M. E., Bishop C. W., Doxercalciferol safely suppresses pth levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. American Journal of Kidney Diseases 2004 43 5 877 890 2-s2.0-1942466552 10.1053/j.ajkd.2004.01.012
65. 3 and oral One-Alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. American Journal of Nephrology 1997 17 6 505 510 2-s2.0-0030664584
66. Kiattisunthorn K., Wutyam K., Indranoi A., Vasuvattakul S., Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology 2011 16 3 277 284 2-s2.0-79951963958 10.1111/j.1440-1797.2010.01398.x
67. Hansen D., Rasmussen K., Danielsen H., Meyer-Hofmann H., Bacevicius E., Lauridsen T. G., Madsen J. K., Tougaard B. G., Marckmann P., Thye-Roenn P., Nielsen J. E., Kreiner S., Brandi L., No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney International 2011 80 8 841 850 2-s2.0-80053562092 10.1038/ki.2011.226
68. Joist H. E., Ahya S. N., Giles K., Norwood K., Slatopolsky E., Coyne D. W., Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clinical Nephrology 2006 65 5 335 341 2-s2.0-33646409276
69. Fadem S. Z., Al-Saghir F., Zollner G., Swan S., Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol-a dose equivalency and titration study. Clinical Nephrology 2008 70 4 319 324 2-s2.0-54949139155
70. Mizobuchi M., Finch J. L., Martin D. R., Slatopolsky E., Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney International 2007 72 6 709 715 2-s2.0-34548509897 10.1038/sj.ki.5002406
71. Becker L. E., Koleganova N., Piecha G., Noronha I. L., Zeier M., Geldyyev A., Kökeny G., Ritz E., Gross M.-L., Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. American Journal of Physiology. Renal Physiology 2011 300 3 F772 F782 2-s2.0-79954467253 10.1152/ajprenal.00042.2010
72. Noonan W., Koch K., Nakane M., Ma J., Dixon D., Bolin A., Reinhart G., Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrology Dialysis Transplantation 2008 23 12 3824 3830 2-s2.0-56749156678 10.1093/ndt/gfn375
73. 2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney International 2003 63 6 2020 2027 2-s2.0-0038188729 10.1046/j.1523-1755.2003.00029.x
74. Balint E., Marshall C. F., Sprague S. M., Effect of the vitamin D analogues paricalcitol calcitriol on bone mineral in vitro. American Journal of Kidney Diseases 2000 36 4 789 796 2-s2.0-0033810843
75. Nakane M., Fey T. A., Dixon D. B., Ma J., Brune M. E., Li Y. C., Wu-Wong J. R., Differential effects of Vitamin D analogs on bone formation and resorption. Journal of Steroid Biochemistry and Molecular Biology 2006 98 1 72 77 2-s2.0-30944448050 10.1016/j.jsbmb.2005.07.007
76. Cozzolino M., Stucchi A., Rizzo M. A., Soldati L., Cusi D., Ciceri P., Brenna I., Elli F., Gallieni M., Vitamin D receptor activation and prevention of arterial ageing. Nutrition, Metabolism & Cardiovascular Diseases 2012 22 7 547 552
77. 3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation 2002 110 2 229 238 2-s2.0-0036073755 10.1172/JCI200215219
78. Tan X., Li Y., Liu Y., Paricalcitol attenuates renal interstitial fibrosis in obstructive nphropathy. Journal of the American Society of Nephrology 2006 17 12 3382 3393
79. Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C., Vitamin D: modulator of the immune system. Current Opinion in Pharmacology 2010 10 4 482 496 2-s2.0-77955251897 10.1016/j.coph.2010.04.001
80. Tan X., Wen X., Liu Y., Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestrtion of NFkB signaling. Journal of the American Society of Nephrology 2008 19 9 1741 1752 10.1681/ASN.2007060666.
81. De Zeeuw D., Agarwal R., Amdahl M., Audhya P., Coyne D., Garimella T., Parving H.-H., Pritchett Y., Remuzzi G., Ritz E., Andress D., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. The Lancet 2010 376 9752 1543 1551 2-s2.0-78149359262 10.1016/S0140-6736(10)61032-X
82. Tamez H., Zoccali C., Packham D., Wenger J., Bhan I., Appelbaum E., Pritchett Y., Chang Y., Agarwal R., Wanner C., Lloyd-Jones D., Cannata J., Thompson B. T., Andress D., Zhang W., Singh B., Zehnder D., Pachika A., Manning W. J., Shah A., Solomon S. D., Thadhani R., Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. American Heart Journal 2012 164 6 902 909 10.1016/j.ahj.2012.09.018
83. Thadhani R., Appelbaum E., Pritchett Y., Chang Y., Wenger J., Tamez H., Bhan I., Agarwal R., Zoccali C., Wanner C., Lloyd-Jones D., Cannata J., Thompson B. T., Andress D., Zhang W., Packham D., Singh B., Zehnder D., Shah A., Pachika A., Manning W. J., Solomon S. D., Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease. The PRIMO randomized controlled trial. Journal of the American Medical Association 2012 307 7 674 684
84. Izquierdo M. J., Cavia M., Muñiz P., de Francisco A. L., Arias M., Santos J., Abaigar P., Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrology 2012 13 article 159 10.1186/1471-2369-13- 159
85. Coronel F., Cigarran S., Gomis A., Rodríguez-Cubillo B., Herrero J. A., Delgado P., Delgado J., Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol ? a preliminary study. Clinical Nephrology 2012 78 2 93 99
86. Tentori F., Hunt W. C., Stidley C. A., Rohrscheib M. R., Bedrick E. J., Meyer K. B., Johnson H. K., Zager P. G., Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney International 2006 70 10 1858 1865 2-s2.0-33750576187 10.1038/sj.ki.5001868
87. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J. M., Thadhani R., Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New England Journal of Medicine 2003 349 5 446 456 2-s2.0-0042343804 10.1056/NEJMoa022536
88. Brancaccio D., Cozzolino M., Cannella G., Messa P., Bonomini M., Cancarini G., Caruso M. R., Cascone C., Costanzo A. M., Di Luzio Paparatti U., Mazzaferro S., Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood Purification 2011 32 2 124 132 2-s2.0-79957538341 10.1159/000325454
89. Tentori F., Albert J. M., Young E. W., Blayney M. J., Robinson B. M., Pisoni R. L., Akiba T., Greenwood R. N., Kimata N., Levin N. W., Piera L. M., Saran R., Wolfe R. A., Port F. K., The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the dialysis outcomes and practice patterns study. Nephrology Dialysis Transplantation 2009 24 3 963 972 2-s2.0-60749091527 10.1093/ndt/gfn592
90. Cozzolino M., Brancaccio D., Cannella G., Messa P., Gesualdo L., Marangella M., LoDeserto C., Pozzato M., Rombolà G., Costanzo A. M., Paparatti U. L., Mazzaferro S., VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pgml results of the Italian Faro survey. Nephrology Dialysis Transplantation 2012 273 588 594
91. Beaubrun A. C., Brookhart M. A., Sleath B., Wang L., Kshirsagar A. V., Trends and variations in intravenous vitamin D use among hemodialysis patients in the United States. Renal Failure 2013 35 1 1 8
92. Rosery H., Bergemann R., Marx S. E., Boehnke A., Melnick J., Sterz R., Williams L., Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clinical Drug Investigation 2006 26 11 629 638 2-s2.0-33750425045 10.2165/00044011-200626110-00002
93. Nuijten M., Andress D. L., Marx S. E., Curry A. S., Sterz R., Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clinical Drug Investigation 2010 30 8 545 557 2-s2.0-77954181846 10.2165/11536310-000000000-00000
94. Roggeri D. P., Mazzaferro S., Brancaccio D., Cannella G., Messa P., Di Luca M., Morosetti M., Costanzo A. M., Paparatti U. L., Cornago D., Cozzolino M., Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects a cost consequences analysis of data from the FARO study. Journal of Medical Economics 2012 15 6 1110 1117
95. Cozzolino M., Galassi A., Brancaccio D., Cinacalcet, paricalcitol, or both? Nephrology Dialysis Transplantation 2007 22 10 3087 2-s2.0-36049042639 10.1093/ndt/gfm423
96. Fishbane S., Shapiro W. B., Corry D. B., Vicks S. L., Roppolo M., Rappaport K., Ling X., Goodman W. G., Turner S., Charytan C., Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clinical Journal of the American Society of Nephrology 2008 3 6 1718 1725 2-s2.0-58149334973 10.2215/CJN.01040308
97. Ketteler M., Martin K. J., Cozzolino M., Goldsmith D., Sharma A., Khan S., Dumas E., Amdahl M., Marx S., Audhya P., Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for treatment of secondary hyperparathyroidism in patients receiving haemodialysis results of the IMPACT SHP study. Nephrology Dialysis Transplantation 2012 27 5 1942 1949
98. Raggi P., Chertow G. M., Torres P. U., Csiky B., Naso A., Nossuli K., Moustafa M., Goodman W. G., Lopez N., Downey G., Dehmel B., Floege J., The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology Dialysis Transplantation 2011 26 4 1327 1339 2-s2.0-79953903052 10.1093/ndt/gfq725
99. Ureña-Torres P. A., Floege J., Hawley C. M., Pedagogos E., Goodman W. G., Pétavy F., Reiner M., Raggi P., Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrology Dialysis Transplantation 2013 28 1 146 152
100. Chertow G. M., Block G. A., Correa-Rotter R., Drüeke T. B., Floege J., Goodman W. G., Herzog C. A., Kubo Y., London G. M., Mahaffey K. W., Mix T. C., Moe S. M., Trotman M. L., Wheeler D. C., Parfrey P. S., Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. The New England Journal of Medicine 2012 367 26 2482 2494